Charles Kent Osborne
#137,817
Most Influential Person Now
Charles Kent Osborne's AcademicInfluence.com Rankings
Charles Kent Osbornebiology Degrees
Biology
#9555
World Rank
#12773
Historical Rank
Molecular Biology
#1325
World Rank
#1352
Historical Rank

Download Badge
Biology
Charles Kent Osborne's Degrees
- PhD Molecular Biology Stanford University
- Bachelors Biochemistry University of California, Berkeley
Why Is Charles Kent Osborne Influential?
(Suggest an Edit or Addition)Charles Kent Osborne's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. (2008) (1796)
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. (2010) (1260)
- Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. (1993) (807)
- The value of estrogen and progesterone receptors in the treatment of breast cancer (1980) (756)
- Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. (2003) (720)
- Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu (1992) (643)
- Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. (2005) (482)
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. (1992) (477)
- Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. (2005) (464)
- Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. (1985) (443)
- Steroid hormone receptors in breast cancer management (2004) (419)
- Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. (1994) (413)
- Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. (1984) (383)
- Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. (1995) (379)
- Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. (1987) (377)
- Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. (1998) (364)
- Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action (2004) (361)
- Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. (1989) (361)
- Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. (1999) (337)
- Aberrant Subcellular Localization of BRCA1 in Breast Cancer (1995) (336)
- Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. (1995) (331)
- Tamoxifen in the treatment of breast cancer. (1998) (317)
- Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. (1983) (306)
- Significance of axillary lymph node metastasis in primary breast cancer. (1999) (279)
- The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. (2015) (279)
- Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. (1989) (272)
- HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer (2004) (268)
- Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. (1999) (267)
- Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. (1991) (263)
- Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. (2008) (257)
- Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. (1989) (251)
- The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. (1993) (251)
- Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. (1976) (245)
- Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells (1988) (245)
- Epidermal growth factor stimulation of human breast cancer cells in culture. (1980) (244)
- Location of BRCA1 in Human Breast and Ovarian Cancer Cells (1996) (240)
- Histologic progression in non-Hodgkin's lymphoma. (1982) (238)
- Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. (1999) (231)
- Time-dependence of hazard ratios for prognostic factors in primary breast cancer (2004) (225)
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial (2009) (224)
- Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. (2000) (220)
- Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. (2013) (219)
- Binding of CtIP to the BRCT Repeats of BRCA1 Involved in the Transcription Regulation of p21 Is Disrupted Upon DNA Damage* (1999) (210)
- Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. (1999) (205)
- Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. (1987) (203)
- Multiple estrogen receptor assays in human breast cancer. (1983) (194)
- Biological differences among MCF-7 human breast cancer cell lines from different laboratories (2005) (190)
- Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions* (2001) (166)
- bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. (1997) (164)
- Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. (1978) (160)
- Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. (2001) (158)
- Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. (1988) (157)
- An autopsy study of histologic progression in non‐Hodgkin's lymphomas 192 cases from the national cancer institute (1983) (156)
- Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. (1992) (153)
- Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. (1990) (148)
- Measurement of steroid hormone receptors in breast cancer patients on tamoxifen (2004) (144)
- Tamoxifen resistance in breast cancer. (1993) (143)
- Telomerase activity and survival of patients with node-positive breast cancer. (1997) (142)
- bcl‐2 and apoptosis in lymph node positive breast carcinoma (1998) (136)
- Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth (2002) (134)
- Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. (1989) (127)
- Tamoxifen in premenopausal patients with metastatic breast cancer: a review. (1991) (121)
- Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. (1992) (119)
- Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. (1984) (117)
- Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. (1996) (116)
- Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. (1983) (116)
- Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. (1992) (113)
- Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. (1995) (109)
- Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. (2000) (106)
- Regulation of breast cancer growth by insulin-like growth factors (1990) (104)
- In vitro model systems for the study of hormone-dependent human breast cancer. (1977) (104)
- Mechanisms of tamoxifen resistance (2004) (102)
- Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. (1988) (97)
- Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. (2001) (95)
- Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. (1992) (91)
- The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth (2004) (87)
- Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. (2004) (87)
- Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. (2003) (79)
- Heat shock proteins and drug resistance (2004) (79)
- Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. (1991) (74)
- Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. (1998) (73)
- Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. (2006) (72)
- High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer (2001) (66)
- Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. (1980) (66)
- Breast cancer mortality and diet in the United States. (1979) (65)
- Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. (1979) (64)
- Steroid hormone receptors in the management of human breast cancer. (1980) (64)
- Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. (1981) (63)
- Prognostic factors for breast cancer: have they met their promise? (1992) (63)
- Oestrogen receptors and breast cancer (1997) (61)
- Steroid hormone receptors and carcinoma of the breast. (1982) (59)
- Antitumor activity and murine pharmacokinetics of parenteral acronycine. (1989) (56)
- Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. (2006) (54)
- Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. (1997) (54)
- Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. (1997) (51)
- Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. (2009) (50)
- Molecular genetic studies of early breast cancer evolution (2004) (50)
- Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. (1994) (49)
- Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). (1998) (47)
- Mechanisms for tamoxifen resistance in breast cancer: Possible role of tamoxifen metabolism (1993) (46)
- Prognostic factors in breast cancer. (1989) (45)
- Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. (1990) (45)
- HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. (2000) (45)
- Cytological evaluation of biological prognostic markers from primary breast carcinomas (1997) (44)
- Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. (1999) (43)
- Prognostic factors in breast cancer. (1992) (43)
- Extranodal presentation of non‐Hodgkin's lymphomas in the testis (1976) (41)
- Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1995) (40)
- Perturbation by insulin of human breast cancer cell cycle kinetics. (1984) (40)
- Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. (1991) (38)
- Low SAFB levels are associated with worse outcome in breast cancer patients (2010) (38)
- Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. (2002) (37)
- Insights into the role of progesterone receptors in breast cancer. (2005) (37)
- Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells (1996) (36)
- Hormone receptors in primary and advanced breast cancer. (1980) (36)
- Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. (2005) (34)
- Immunohistochemical studies of early breast cancer evolution (2004) (32)
- Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. (1983) (32)
- Heterogeneity in hormone receptor status in primary and metastatic breast cancer. (1985) (32)
- Optimizing Chemotherapy-Free Survival for the ER/HER2-Positive Metastatic Breast Cancer Patient (2011) (30)
- Targeting the EGF receptor in breast cancer treatment (2004) (30)
- Current use of steroid hormone receptor assays in the treatment of breast cancer. (1978) (29)
- Autocrine and paracrine growth regulation of breast cancer: Clinical implications (2005) (28)
- Effects of estrogens and antiestrogens on cell proliferation: implications for the treatment of breast cancer. (1988) (28)
- Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. (1988) (27)
- Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. (1987) (25)
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
- Human Breast Cancer in Tissue Culture: The Effects of Hormones (1978) (24)
- Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. (1995) (23)
- Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). (1992) (23)
- The management of clinically localized prostate cancer. National Institutes of Health Consensus Development Conference, June 15-17, 1987. (1987) (22)
- Combined chemo-hormonal therapy in breast cancer: A hypothesis (2005) (19)
- Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. (1992) (19)
- DNA flow cytometry in early breast cancer: a step in the right direction. (1989) (18)
- Prognostic factors: Rationale and methods of analysis and integration (2004) (18)
- The use of steroïd hormone receptors in the treatment of human breast cancer: a review. (1979) (17)
- Circulating tumor DNA--ready for prime time? (2013) (17)
- A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). (2012) (16)
- A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. (2012) (16)
- Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer (2005) (15)
- Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration (2004) (15)
- Pure Antiestrogens The Most Important Advance in the Endocrine Therapy of Breast Cancer since 1896? a (1996) (15)
- Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. (2003) (15)
- Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. (1981) (15)
- A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study) (2004) (14)
- Modern approaches to the treatment of breast cancer. (1980) (14)
- Diseases of the breast: Fifth edition (2014) (14)
- Bisantrene, an active drug in patients with advanced breast cancer. (1984) (13)
- Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. (1994) (13)
- Insulin stimulation of fatty acid synthesis in human breast cancer cells. (1977) (12)
- Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study (1998) (12)
- Adjuvant therapy in node-negative breast cancer (1989) (11)
- The use of restriction fragment polymorphisms to identify the cell line MCF-7 (2005) (10)
- Endocrine Therapies in Breast and Prostate Cancer (2011) (10)
- The role of growth factors in breast cancer (1988) (9)
- Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. (1989) (8)
- Urokinase-type receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies (1994) (8)
- Estrogen Receptor and Prognosis in Breast Cancer (1981) (8)
- Endocrine therapy of human breast cancer grown in nude mice (1987) (8)
- Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. (2005) (7)
- Tamoxifen metabolism as a mechanism for resistance (1995) (7)
- Cells Inhibitor of Estrogen Receptor-negative Human Breast Cancer : Potential Autocrine Growth β Transforming Growth Factor (2006) (7)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. (2003) (6)
- Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). (1996) (6)
- Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. (2001) (5)
- Therapy for cancer of the breast. Current status of steroid hormone receptors. (1979) (5)
- Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay (2005) (5)
- Cell proliferative indices and DNA content as prognostic factors in primary breast cancer. (1989) (5)
- Anaphylactoid reactions associated with bisantrene infusions (1983) (5)
- Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model (1988) (5)
- Evaluation of patients for metastasis prior to primary therapy (2014) (5)
- Athymic nude mouse model for the study of new antioestrogens in breast cancer (1996) (5)
- Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer (1991) (4)
- Bisantrene, biological and clinical effects. (1984) (4)
- Antitumor Activity and Murine Pharmacokinetics of Parenteral Acronycine 1 (2006) (3)
- Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium ‘Breast Cancer – the Development and Validation of New Therapeutics’ (2005) (3)
- Dose intensity as a therapeutic strategy in breast cancer (1991) (3)
- Rapid identification of transfected plasmid expression vectors in cells by PCR. (1991) (3)
- 8 Steroid Receptors in Relation to Response (1988) (3)
- Resistance to endocrine therapy A panel discussion (2005) (3)
- Abstract 319: Role of GPR110 on tumorigenesis and metastasis in HER2+ breast cancer in the context of anti-HER2 drug resistance (2016) (3)
- William Leo McGuire, MD 1937–1992 (1992) (3)
- Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer (2022) (2)
- BRCA1 in clinical breast cancer. (1998) (2)
- Diseases of the Breast 4/e (2009) (2)
- Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells (1983) (2)
- Adjuvant treatment of node-negative breast cancer. (1989) (2)
- Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee. (1994) (2)
- Pain control in breast cancer (2005) (2)
- Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. (1991) (2)
- Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. (1982) (2)
- ER/HER2-Positive Metastatic Breast Cancer Patient Optimizing Chemotherapy-Free Survival for the (2011) (2)
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2003) (2)
- Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer (2004) (1)
- Overexpression Causes Growth Arrest and Multinuclearity and Is Associated with Aneuploidy in Human Breast Cancer 1 (2000) (1)
- SERMs and Breast Cancer Prevention (2002) (1)
- Insulin receptors in human breast cancer: relationship of binding, degradation and biological activity (1976) (1)
- Non-nuclear human estrogen receptor-alpha 36 (hERα-36) is expressed in ER, PR, and Her2 positive or negative breast cancer patients as well as cell lines, and physically interacts with Her2 (2008) (1)
- Abstract 4064: Association of molecular signatures, mutations, and sTILs, with pCR in breast cancer patients in NRG Oncology/NSABP B-52 (2019) (1)
- Translational research in the San Antonio breast cancer SPORE (2004) (1)
- Preface to the fifth edition (2014) (0)
- The Small Heat Shock Protein hsp27 Is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines 1 (2007) (0)
- Interview: The targeted therapy era of breast cancer (2012) (0)
- Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody against the Type I Somatomedin Receptor1 (2006) (0)
- Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. (2011) (0)
- A New Concept of Breast Cancer Growth Regulation and its Potential Clinical Applications (1989) (0)
- SABCS: Research From This Year's Conference (2011) (0)
- Adjuvant endocrine treatment tailoring in 2006 — dream or reality? (2006) (0)
- Receptors - Their prognostic and predictive value (2000) (0)
- Adjuvant therapy for breast cancer. (1988) (0)
- Phase II trial of a new biological response modifier (ImuVert) in advanced prostate cancer (1989) (0)
- Abstract P3-06-12: Autophagy-mediated survival mechanism to c-Src inhibitor therapy in triple negative breast cancer (2020) (0)
- Tumor C haracteristics a nd C linical O utcome o f T ubular and M ucinous B reast C arcinomas (1999) (0)
- Spreading the word, but not too thinly (2004) (0)
- Epidermal Growth Factor Stimulation of Human Breast Cancer Cells in Culture 1 (2006) (0)
- Hematopoietic growth factors in breast cancer — Overview (1991) (0)
- Immunoreactive a. Transforming Growth Factor Activity in Effusions from Cancer Patients as a Marker of Tumor Burden and Patient Prognosis1 (2006) (0)
- Toremifene — panel discussion and summary (1990) (0)
- Polypeptide growth factors: their potential value in the management of breast cancer patients. (1992) (0)
- Growth Factor-mediated Signaling and Growth-negative MCF-7 Cells Restores both Estrogen and Insulin-like α in Estrogen Receptor α Re-expression of Estrogen Receptor Updated (2001) (0)
- The MAPK inhibitor, MKP3, is an estrogen receptor α coactivator associated with tamoxifen resistance (2005) (0)
- Abstract P6-11-01: A broad spectrum therapeutic strategy for TNBC revealed by a new pathway that coordinates oncogenic RTKs (2015) (0)
- The hypothesis of hormonal manipulation of tumor cells in combination with chemotherapy (1986) (0)
- Potential and problems with growth of breast cancer in a human tumor cloning system (2005) (0)
- Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer (2020) (0)
- Transforming Growth Factor ß:Potential Autocrine Growth Inhibitor of Estrogen Receptor-negative Human Breast Cancer Cells1 (2006) (0)
- Abstract 2296: Identification of novel nuclear receptor targets in estrogen receptor negative breast cancer (2011) (0)
- Significance o f A xillary L ymph N ode M etastasis in P rimary B reast C ancer (1999) (0)
- 151 Effects of antiestrogens and estrogens on proliferation of human breast cancer cells; in vitro and in vivo models. (1983) (0)
- Megestrol acetate in breast cancer — A panel discussion (1989) (0)
- Insulin stimulates acetyl Co A carboxylase in human breast cancer cells: Possible mechanism of somatotrophic effect of insulin (1978) (0)
- Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer (2023) (0)
- Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. (1996) (0)
- Human Breast Cancer Cell Cycle Synchronization by Estrogens and Antiestrogens in Culture 1 (2006) (0)
- Antitumor Activity and Murine Pharmacokinetics (2006) (0)
- Clinical Implications of Tamoxifen's Mechanism of Action (1988) (0)
- Hormone receptors in the management of breast cancer. (1984) (0)
- Adjuvant chemotherapy (1986) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Charles Kent Osborne?
Charles Kent Osborne is affiliated with the following schools: